Trial Profile

A phase III randomized, double-blind, placebo-controlled, multinational trial evaluating efficacy and safety of an adjunctive cenobamate therapy in adult patients aged 18–70 with uncontrolled partial-onset (focal) seizures on 1-3 ASMs

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Nov 2025 New trial record
30 Sep 2025 According to SK biopharmaceuticals media release, Ono pharmaceutical (partnered with SK biopharmaceuticals) submitted an application for the manufacturing and marketing approval of cenobamate (ONO-2017) for the treatment of partial-onset seizures, with or without secondary generalized seizures. based on the results of the trial.
30 Sep 2025 Results published in the Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com